Various inhibitors of cell metabolism have been used as anticancer drugs. However, these agents also have profound effects on normal cells, leading to severe side-effects. Liposomes have been used as slow-releasing capsules to alter the plasma clearance and tissue distribution of anticancer drugs. Liposomes can also be used to target cancer cells by attachment of an antibody against the surface molecules of these cells. The anti-cancer activities of these liposomes are, however, not sufficiently high for practical cancer therapy (Wright and Huang., 1989) , perhaps owing to the degradation of most drugs by lysosomal enzymes after the liposomes are taken up by endocytosis (Wright and Huang., 1989; Casellas et al., 1988; Colombatti et al., 1990) .
Protein toxins are another type of candidate molecule that has potential anti-cancer activity (Wawrzynczak, 1991) . Immunotoxins, prepared by conjugation of subunits of various protein toxins with anti-tumour antibodies, show cytotoxicity to target cells in vitro. However, the therapeutic efficacy of immunotoxins is currently limited by the relatively weak action of immunotoxins in vivo. One of the reasons is that most immunotoxins are degraded by lysosomal enzymes after cells take them up by endocytosis (Wawrzynczak, 1991) . To overcome this inefficiency a system that allows these molecules to penetrate directly into cells is required.
Previously we reported the preparation and characterisation of fusogenic liposomes, which have virus envelope proteins on their surface (Uchida et al., 1979; Nakanishi et al., 1985; Kato et al., 1991a,b; Nakanishi and Okada, 1993; Nakanishi et al., 1995; M Nakanishi et al, manuscript in preparation) . The fusogenic liposome fuses with the cell membrane in a receptor-dependent manner similiar to the native virus particle. This system is unique in comparison with other drug delivery systems, because the fusogenic liposomes can deliver their contents directly into the cytoplasm. Using these liposomes, we have delivered, intact macromolecules such as proteins and DNA into tissue cells as well as cultured cells (Uchida et al., 1979; Nakanishi et al., 1985; Kato et al., 1991a,b; Nakanishi and Okada, 1993; Nakanishi et al., 1995; M Nakanishi et al., manuscript in preparation) .
We also found that fusogenic liposomes containing fragment A of diphtheria toxin (DTA) killed cultured cells quite efficiently (Uchida et al., 1979; Nakanishi et al., 1985; Nakanishi et al., 1995; M Nakanishi et al., manuscript in preparation) . DTA is known to kill cells by inactivating elongation factor 2 even when only one molecule of this protein is introduced into the cytoplasm, whereas it is absolutely non-toxic even if it is taken up by endocytosis, because it cannot reach the cytoplasm owing to degradation by lysosomal enzymes (Yamaizumi et al., 1978; Uchida, 1982) .
In this paper, we report that administration of unilamellar fusogenic liposomes containing DTA resulted in complete remission in mice carrying sarcoma-180 (S-180) cells without producing any side-effects. (FCS) . Primary human peripheral lymphocytes were prepared using Mono-Poly Resolving Medium (Dainippon Pharmaceutical, Osaka, Japan) and cultured with RPMI-1640 medium supplemented with 10% FCS, 50 jiM 2-mercaptoethanol and 5 jig ml-' Phaseolus vulgaris Agglutinin-P Sendai virus (Z strain) was prepared as described previously (Nakanishi et al., 1985 (Nakanishi et al., 1995) . Under these conditions, about 200 molecules of DTA were encapsulated in a liposome particle.
Materials and methods

Materials
Unilamellar fusogenic liposomes were prepared as described elsewhere (Nakanishi et al., 1995 (Nakanishi et al., 1995) . For inactivation of the genomic RNA of Sendai virus purified fusogenic liposomes were treated with ultraviolet irradiation (2 000 J m-2) just before use.
The amount of DTA encapsulated within liposomes was determined by measuring NAD-elongation factor 2 (EF2)-ADP-ribosyl transferase (ADPR) activity (Carroll and Collier., 1988) after lysis by Triton X-100, using EF2 partially purified from rabbit liver (Takamatsu et al., 1986) . Liposome and fusogenic liposome suspensions at the optical density of 1.0 at 540 nm (OD540= 1.0) contained 3.61 and 0.52 Mg DTA ml-' respectively . Before lysis with detergent, these samples showed no NAD/EF/2/ADPR activity, indicating that most of the DTA was present inside the liposomes.
Protein was determined by a Bio-Rad protein assay kit using bovine serum albumin as a standard. Lipid was measured with the Phospholipids B-Test Wako (Wako, Osaka, Japan). The haemagglutinating activity was determined as described previously (Kato et al., 1991a (Table I) . These results showed that fusogenic liposomes also fused with S-180 cells in the abdominal cavity of the mice. We also examined the survival of the mice given various kinds of liposomes ( Figure  2 and Table II To compare the efficiency of the fusogenic liposomes in delivering DTA to S-180 cells in vitro and in vivo, we determined the amount of DTA associated with S-180 cells (Table III) . In in vitro experiments, the amount of DTA delivered into 1 x 106 S-180 cells (0.64 ng) was 25% of that inoculated with fusogenic liposomes (2.6 ng). In in vivo experiments, the amount of DTA delivered (0.52 ng) was 0.4% of that inoculated with fusogenic liposomes (130 ng).
These data showed that the fusogenic liposomes fused with S-180 cells 60 times less efficiently in vivo than in vitro, and that about 0.5 ng of DTA was sufficient to kill 1 x 106 S-180 cells both in vitro and in vivo if delivered by the fusogenic liposomes. This was in great contrast to the result that 10 jug of pure DTA alone had no effect on growth of S-180 cells in vivo (see above).
Side-effects caused by administration offusogenic liposomes We also examined whether fusogenic liposomes containing DTA affected other functions of living mice when injected i.p. Figure 3 shows Comparison with other anti-tumour drugs We also examined the effect of mitomycin C (MMC), an antibiotic with anti-tumour activity against various kinds of tumours (Crooke, 1979) , on S-180 ascitic tumours. The i.p. administration of MMC at the dose of 2.5 and 5.0 mg kg-' of body weight resulted in tumour-suppressive effects similar to those of fusogenic liposomes containing DTA with OD,40 of 0.5 and 1.0 (data not shown). However, the body weight was decreased by over 5% on the day following the injection of MMC (data not shown). Furthermore, the loss of hair, sores of the skin on the abdomen and the loss of whiskers were observed in all mice. The degree of these side-effects was in striking contrast to the absence of side-effects caused by fusogenic liposomes.
Discussion
Fragment A of diphtheria toxin (DTA), the N-terminal peptide of the toxin with a molecular weight of 22 000, is absolutely non-toxic when it is located outside the cell membrane because it cannot enter the cytoplasm. However, if even one molecule of this peptide enters the cytoplasm, it can kill the cell (Yamaizumi et al., 1978; Uchida, 1982 Surprisingly, the administration of fusogenic liposomes containing DTA did not result in any severe side-effects or altered appearance, even though the fusogenic liposomes have the capacity to deliver their contents into a variety of cells. The abdominal side of the stomach, liver, intestine, kidney and spleen were histologically normal (data not shown). One of the possible explanations for this selective toxicity to tumour cells is that the extracellular matrix of these organs might prevent the fusion of fusogenic liposomes with the cell membrane, but the detailed mechanism of this apparent specificity remains as a future problem.
There are other characteristics that may contribute to low non-specific toxicity to the body. The average diameter of the injected fusogenic liposomes containing DTA was 380 nm (Nakanishi et al., 1995) , and therefore they would not circulate through the whole body. Furthermore, DTA is non-toxic even when it is released from fusogenic liposomes. Administration of 10 ug of DTA (alone) did not show any effects in the mice (data not shown). These characteristics contrast with those of other low molecular weight anti-cancer drugs, and also may contribute to the absence of side-effects.
Although various methods have been developed to introduce foreign genetic materials into cells, only a few techniques have been developed to deliver proteins into the cytoplasm. The fusogenic liposomes in our system can deliver various kinds of proteins directly and efficiently into the cytoplasm because they fuse with the cell membrane through the mechanism of Sendai virus infection (Nakanishi et al., 1985) . The efficiency of fusogenic liposomes in introducing their contents into the cells is the same as that of infection with intact Sendai virus (Nakanishi et al., 1995) . Huang et al. reported that pH-sensitive immunoliposomes can deliver encapsulated DTA into the cytoplasm (Wang and Huang, 1989; Collins et al., 1990; Litzinger and Huang, 1992; Tari et al., 1994) . However, these pH-sensitive immunoliposomes showed protein synthesis inhibition of only 50-70% at maximum, and could not kill all the cells (Collins et al., 1990; Tari et al., 1990) . Judging from the concentration of DTA required to kill the cells, our system is far more efficient. This superior efficiency in protein delivery is another important aspect of possible cancer therapy using DTA.
The results described herein are a first attempt to examine the potential activity of fusogenic liposomes in cancer therapy. Fusogenic liposomes containing DTA may be a potential new therapeutic approach in the treatment of ascitic tumours and may also be effective in the local treatment of solid tumours and the treatment of malignant pleural effusion. 
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